Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of Bailing tablets in stage 3 chronic kidney disease (non-dialysis)
ChiCTR2200063918Phase 4Not yet recruiting
- Sponsor
- Guangzhou Hospital of Integrated Traditional and Western Medicine
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of bailing jiaonang in chronic kidney disease (CKD) (4 arms), sponsored by Guangzhou Hospital of Integrated Traditional and Western Medicine. Primary endpoint: urinary albumin. Planned start Sep 2022; status: not yet recruiting.
02
Drugs
bailing jiaonang
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on ChiCTR2200063918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200063918.